143 related articles for article (PubMed ID: 38015388)
1. Evaluating implementation of NCCN guideline-directed genetic screening recommendations for patients with pancreatic ductal adenocarcinoma.
Ghosh AK; Bhushan S; Abidoye O; Robinson SS; Rynarzewska AI; Sampat D
Cancer Causes Control; 2024 Apr; 35(4):679-684. PubMed ID: 38015388
[TBL] [Abstract][Full Text] [Related]
2. White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part I, AJCC staging system, NCCN guidelines, and borderline resectable disease.
Kulkarni NM; Soloff EV; Tolat PP; Sangster GP; Fleming JB; Brook OR; Wang ZJ; Hecht EM; Zins M; Bhosale PR; Arif-Tiwari H; Mannelli L; Kambadakone AR; Tamm EP
Abdom Radiol (NY); 2020 Mar; 45(3):716-728. PubMed ID: 31748823
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of Universal Point-of-Care Genetic Testing in Diverse Patients With Pancreatic Ductal Adenocarcinoma.
Drogan CM; Kindler HL; Gao G; Kupfer SS
JCO Precis Oncol; 2023 Jan; 7():e2200196. PubMed ID: 36689696
[TBL] [Abstract][Full Text] [Related]
4. Burden of hereditary cancer susceptibility in unselected patients with pancreatic ductal adenocarcinoma referred for germline screening.
Cremin C; Lee MK; Hong Q; Hoeschen C; Mackenzie A; Dixon K; McCullum M; Nuk J; Kalloger S; Karasinska J; Scudamore C; Kim PTW; Donnellan F; Lam ECS; Lim HJ; Neben CL; Stedden W; Zhou AY; Schaeffer DF; Sun S; Renouf DJ; Schrader KA
Cancer Med; 2020 Jun; 9(11):4004-4013. PubMed ID: 32255556
[TBL] [Abstract][Full Text] [Related]
5. Modified National Comprehensive Cancer Network Criteria for Assessing Resectability of Pancreatic Ductal Adenocarcinoma.
Noda Y; Goshima S; Kawada H; Kawai N; Miyoshi T; Matsuo M; Bae KT
AJR Am J Roentgenol; 2018 Jun; 210(6):1252-1258. PubMed ID: 29629801
[TBL] [Abstract][Full Text] [Related]
6. Impact of comprehensive family history and genetic analysis in the multidisciplinary pancreatic tumor clinic setting.
Everett JN; Dettwyler SA; Jing X; Stender C; Schmitter M; Baptiste A; Chun J; Kawaler EA; Khanna LG; Gross SA; Gonda TA; Beri N; Oberstein PE; Simeone DM
Cancer Med; 2023 Feb; 12(3):2345-2355. PubMed ID: 35906821
[TBL] [Abstract][Full Text] [Related]
7. Recommendations for Palliative and Hospice Care in NCCN Guidelines for Treatment of Cancer.
Mo L; Urbauer DL; Bruera E; Hui D
Oncologist; 2021 Jan; 26(1):77-83. PubMed ID: 32915490
[TBL] [Abstract][Full Text] [Related]
8. BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts.
Lucas AL; Frado LE; Hwang C; Kumar S; Khanna LG; Levinson EJ; Chabot JA; Chung WK; Frucht H
Cancer; 2014 Jul; 120(13):1960-7. PubMed ID: 24737347
[TBL] [Abstract][Full Text] [Related]
9. Disparities in NCCN Guideline-Compliant Care for Patients with Early-Stage Pancreatic Adenocarcinoma at Minority-Serving versus Non-Minority-Serving Hospitals.
Lima HA; Alaimo L; Moazzam Z; Endo Y; Woldesenbet S; Katayama E; Munir MM; Shaikh C; Ruff SM; Dillhoff M; Beane J; Cloyd J; Ejaz A; Resende V; Pawlik TM
Ann Surg Oncol; 2023 Jul; 30(7):4363-4372. PubMed ID: 36800128
[TBL] [Abstract][Full Text] [Related]
10. Compliance with the Current NCCN Guidelines and Its Critical Role in Pancreatic Adenocarcinoma.
Petersen JM; Jhala DN
Lab Med; 2023 Jan; 54(1):e1-e9. PubMed ID: 35706071
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic and therapeutic recommendations in pancreatic ductal adenocarcinoma. Recommendations of the Working Group of the Polish Pancreatic Club.
Winter K; Talar-Wojnarowska R; Dąbrowski A; Degowska M; Durlik M; Gąsiorowska A; Głuszek S; Jurkowska G; Kaczka A; Lampe P; Marek T; Nasierowska-Guttmejer A; Nowakowska-Duława E; Rydzewska G; Strzelczyk J; Śledziński Z; Małecka-Panas E
Prz Gastroenterol; 2019; 14(1):1-18. PubMed ID: 30944673
[TBL] [Abstract][Full Text] [Related]
12. High-resolution pancreatic computed tomography for assessing pancreatic ductal adenocarcinoma resectability: a multicenter prospective study.
Lee DH; Ha HI; Jang JY; Lee JW; Choi JY; Bang S; Lee CH; Kim WB; Lee SS; Kim SC; Kang BK; Lee JM
Eur Radiol; 2023 Sep; 33(9):5965-5975. PubMed ID: 36988715
[TBL] [Abstract][Full Text] [Related]
13. Implications of Multigene Panel Testing on Psychosocial Outcomes: A Comparison of Patients With Pancreatic and Breast or Ovarian Cancer.
Koptiuch C; Espinel WF; Kohlmann WK; Zhao J; Kaphingst KA
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250392
[TBL] [Abstract][Full Text] [Related]
14. Assessment of the external validity of the National Comprehensive Cancer Network (NCCN) guidelines for pancreatic ductal adenocarcinoma in a population of older patients aged 70 years and older.
Rodriquenz MG; Negrete-Najar JP; Sam C; Sehovic M; Extermann M
J Geriatr Oncol; 2022 Sep; 13(7):952-961. PubMed ID: 35597730
[TBL] [Abstract][Full Text] [Related]
15. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
16. Implementing Systematic Genetic Counseling and Multigene Germline Testing for Individuals With Pancreatic Cancer.
Chittenden A; Haraldsdottir S; Ukaegbu C; Underhill-Blazey M; Gaonkar S; Uno H; Brais LK; Perez K; Wolpin BM; Syngal S; Yurgelun MB
JCO Oncol Pract; 2021 Feb; 17(2):e236-e247. PubMed ID: 33439686
[TBL] [Abstract][Full Text] [Related]
17. Significant detection of new germline pathogenic variants in Australian Pancreatic Cancer Screening Program participants.
Murali K; Dwarte TM; Nikfarjam M; Tucker KM; Vaughan RB; Efthymiou M; Collins A; Spigelman AD; Salmon L; Johns AL; Williams DB; Delatycki MB; John T; Stoita A
Hered Cancer Clin Pract; 2021 Aug; 19(1):33. PubMed ID: 34399810
[TBL] [Abstract][Full Text] [Related]
18. Inherited predisposition to pancreatic cancer.
Hilfrank KJ; Rustgi SD; Kastrinos F
Semin Oncol; 2021 Feb; 48(1):2-9. PubMed ID: 33773812
[TBL] [Abstract][Full Text] [Related]
19. Prediction of margin-negative resection of pancreatic ductal adenocarcinoma following neoadjuvant therapy: Diagnostic performance of NCCN criteria for resection vs CT-determined resectability.
Jang JK; Choi SJ; Byun JH; Kim JH; Lee SS; Kim HJ; Yoo C; Kim KP; Hong SM; Seo DW; Hwang DW; Kim SC
J Hepatobiliary Pancreat Sci; 2022 Sep; 29(9):1025-1034. PubMed ID: 35658103
[TBL] [Abstract][Full Text] [Related]
20. Applicability of current NCCN Guidelines for pancreatic adenocarcinoma resectability: analysis and pitfalls.
Garces-Descovich A; Beker K; Jaramillo-Cardoso A; James Moser A; Mortele KJ
Abdom Radiol (NY); 2018 Feb; 43(2):314-322. PubMed ID: 29392370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
